Quantcast
Last updated on April 23, 2014 at 1:22 EDT

Latest Zwitterions Stories

2014-04-04 11:40:41

DRI scientists investigate the link between right-handed and left-handed amino acids A study published this week in PLOS ONE authored by Dr. Henry Sun and his postdoctoral student Dr. Gaosen Zhang of Nevada based research institute DRI provides new evidence that Earth bacteria can do something that is quite unusual. Despite the fact that these bacteria are made of left-handed (L) amino acids, they are able to grow on right-handed (D) amino acids. This DRI study, funded by the NASA...

2014-03-10 23:22:27

The United States market for amino acids was valued at $1.5 billion in 2012 and was estimated at nearly $1.6 billion for 2013. BCC Research expects the market to grow to nearly $2 billion by 2018, and register a five-year compound annual growth rate of 4.5% from 2013 to 2018. Wellesley, Mass (PRWEB) March 10, 2014 According to a new technical market research report Commercial Amino Acids, from BCC Research (http://www.bccresearch.com), the United States market for amino acids was valued...

2013-11-08 16:24:50

MarketReportsChina.com adds Survey of Feed Grade Amino Acids in China Edition (2) and Survey of Diuron in China Edition (2) market research reports to its store. DALLAS, Nov. 8, 2013 /PRNewswire-iReach/ -- Survey of Feed Grade Amino Acids in China Edition (2) market research report says as a major supplier of feed grade amino acids, China is facing opportunities and challenges. Currently, most feed grade amino acids are over capacity and the global economy recovers quite slowly,...

2013-03-11 16:26:00

Keryx to Host Investor Conference Call Tomorrow, Tuesday, March 12, 2013 at 8:30am EDT NEW YORK, March 11, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease (the "Company"), today announced its results for the fourth quarter and year ended December 31, 2012. At December 31, 2012, the Company had...

2013-03-11 12:25:07

QUEBEC CITY, March 11, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that an independent Data Safety Monitoring Board ("DSMB") has recommended discontinuing the ongoing Phase 3 study comparing the efficacy and safety of perifosine to placebo when combined with bortezomib (Velcade(®)) and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma. Based on the outcome of its pre-planned interim...

2013-02-08 20:22:23

NEW YORK, Feb. 8, 2013 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, has filed a class action lawsuit against Keryx Biopharmaceuticals, Inc. ("Keryx" or the "Company") (NasdaqCM: KERX). (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) Keryx and its Chief Executive Officer Ron Bentsur are alleged to have violated Section 10(b) and/or 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. Specifically, the...

2012-12-11 08:27:00

Promising clinical response activity observed in patients with Hodgkin lymphoma QUÉBEC CITY, Dec. 11, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) today announced that final Phase 2 data demonstrated that the combination of perifosine, its oral AKT inhibitor, and sorafenib, was well tolerated by heavily pretreated patients with relapsed/refractory lymphomas. Furthermore, promising clinical response activity was observed in patients with...

2012-11-26 08:24:10

QUÉBEC CITY, Nov. 26, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) today announced that final Phase 2 data for perifosine, its oral AKT inhibitor, combined with sorafenib in patients with relapsed/refractory lymphomas, will be presented at the upcoming American Society of Hematology ("ASH") annual meeting in Atlanta, Georgia, December 8-11, 2012. Data will be disclosed during a poster presentation by Anna Guidetti, MD, of the Fondazione IRCCS...

2012-11-19 08:27:50

QUÉBEC CITY, Nov. 19, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that perifosine, its oral AKT inhibitor, combined with temsirolimus ("TEM"), was well tolerated in an investigator driven Phase 1 clinical trial in recurrent or progressive malignant glioma ("MG"). Data were presented over the weekend by Thomas J. Kaley, MD, Director, Neuro-Oncology Fellowship Program at Memorial Sloan-Kettering Cancer Center,...

2012-11-07 16:28:01

NEW YORK, Nov. 7, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease (the "Company"), today announced its results for the third quarter ended September 30, 2012. At September 30, 2012, the Company had cash, cash equivalents, interest receivable, and investment securities of $20.2 million, as compared to...